Skip to main content

Table 2 Prophylactic Study

From: Evaluation of anti-malarial potency of new pyrazole-hydrazine coupled to Schiff base derivatives

Treatment Dose (mg/kg) Parasitaemia count
Day 3 Day 4 Day 5 (post inoculation)
Control 9.40 ± 1.23 14.40 ± 0.45# 16.37 ± 1.25#
BePINH 2.5 3.75 ± 1.08* 2.92 ± 1.64* 2.77 ± 1.65*
10 3.70 ± 0.64* 2.30 ± 2.72* 2.05 ± 0.72*
15 2.43 ± 0.86* 0.83 ± 0.92* 0.76 ± 1.11*
BePBeH 2.5 3.99 ± 0.74* 2.95 ± 0.49* 2.93 ± 1.06*
10 3.72 ± 0.64* 2.50 ± 0.52* 2.18 ± 0.77*
15 2.46 ± 0.75* 0.91 ± 1.62* 0.79 ± 1.19*
ACT 5 0.51 ± 0.26* 0.26 ± 0.42* 0.10 ± 0.66*
  1. Each value represents the mean ± S.E.M, n = 5
  2. ACT artemisinin-based combination therapy
  3. *,#p < 0.05 compared with control and Day 3, respectively (One-way ANOVA; Dunnett’s post hoc)